NXTC (37) RNAZ (35) PMN (35) AARD (33) ⌘ Pro Terminal →

Rockwell Medical Inc. (RMTI) — RQD Stock Rating Cockpit

$7.07 -3.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.01

Rockwell Medical Inc. (RMTI) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $28.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RMTI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RMTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Rockwell Medical Inc. (NASDAQ: RMTI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $7.07 (-3.28% 1D, market cap $28.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RMTI ranks #954 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RMTI compare to NXTC and RNAZ in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RMTI carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 16.9%, and ROIC of -10.6%. By comparison, NXTC (NextCure Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $28.9M) and RNAZ (TransCode Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $27.6M). Among the 5-stock peer group, RMTI leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RMTI?

▼

Per RMTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001041024), Rockwell Medical Inc. generated $69.3M in revenue (-31.8% YoY), -$5.3M in net income, and -$659.0K in free cash flow against $57.1M in total assets and $8.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $7.01 (-0.78%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RMTI)Realized 20D OHLCV Swing Band: ±12.1%

Deterministic 5-Pillar Attribution (23/100 Composite)

🔍 WHY RMTI SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+6/20 pts (26% of score)

FRED Regime × Technicals: 27% of 52W Range • RSI-14 at 42.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 16.9% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$7.85-7.9% Next Q

Q2 (-2Q)

Grade E$7.23-5.1% Next Q

Q3 (-1Q)

Grade E$6.86+3.1% Next Q

Current

Grade E$7.07-11.1% Hist 90D α

Trajectory: E (31) → E (23)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RMTI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RMTI currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.88) and Max Pain ($7.42) forces dealer call-delta covering toward $13.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RMTI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RMTI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 23%NO 77%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

42.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE27% OF RANGE

L: $5$7.07H: $13

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 11 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on RMTI

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-10.6% ROIC with 16.9% gross margin and -2.24% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (22)

7/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like RMTI

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RMTI)

✓Walkthrough of RMTI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RMTI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.56%🛡️ HOLDING TREND SUPPORT

2026-11-03O $7.31H $7.31L $7.07C $7.07VOL 39.5K

RES: $9.88SUP: $6.69SMA50: $7.88SMA200: $8.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RMTI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RMTI Butterfly Map → + Track RMTI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RMTI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RMTI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RMTI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RMTI)

Health Care Rank #954 of 1016 ⚔️ NXTC vs RMTI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RMTI vs. NXTC, RNAZ, PMN, AARD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rockwell Medical Inc. (RMTI) ranks #954 by composite RQD confidence (23/100, grade E) and #805 by equity capitalization ($28.5M). Within this direct 5-issuer industry benchmark cohort, RMTI leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. NXTC currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with RMTI at 23/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RMTI ACTIVE Rockwell Medical Inc.	E	23/100	—	16.9%	-10.6%	-3.28%	$28.5M	Benchmark Subject
NXTC NextCure Inc.	D-	37/100	—	—	-35.0%	-3.29%	$28.9M	/nxtc-vs-rmti →
RNAZ TransCode Therapeutics Inc.	D-	35/100	—	—	-35.0%	-5.78%	$27.6M	/rnaz-vs-rmti →
PMN ProMIS Neurosciences Inc. (ON)	D-	35/100	—	—	-35.0%	-70.13%	$29.7M	/pmn-vs-rmti →
AARD Aardvark Therapeutics Inc.	E	33/100	—	—	-35.0%	-5.56%	$29.8M	/aard-vs-rmti →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001041024

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rockwell Medical Inc. (RMTI) reported GAAP revenue of $69.3M (-31.8% vs. FY2024 revenue of $101.5M ) , GAAP net income of -$5.3M, operating cash flow of -$659.0K, and free cash flow of -$659.0K (-115.7% YoY). On the balance sheet, RMTI closed FY2025 with $57.1M in total assets against $8.8M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$69.3M	-$5.3M	-$659.0K	-$659.0K	$57.1M	$8.8M
FY2024 (FY)	2024-12-31	$101.5M	-$480.0K	$4.2M	$4.2M	$59.2M	$8.5M
FY2023 (FY)	2023-12-31	$0	-$8.4M	-$9.4M	-$9.4M	—	—

3. RMTI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RMTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RMTI compare to NXTC and RNAZ in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RMTI?

Where is RMTI trading relative to its 50-day, 200-day, and 52-week technical levels?

RMTI last traded at $7.07 (-3.28% on volume of 39,545 shares), positioning the stock -10.28% below its 50-day simple moving average ($7.88) and -13.89% below its 200-day simple moving average ($8.21). Across its 52-week range of $4.89 to $12.90, RMTI sits at the 27.2% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($6.21 to $7.93).

RMTI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell RMTI stock right now?

Rockwell Medical Inc. (RMTI) currently earns a Roarable Rating of E (Strong Sell — SELL) with 23/100 RQD Confidence. Stretched risk/reward at current multiples (-11% return on capital) under elevated 10-year interest-rate pressure.

What is RMTI's 12-month price target and RQD AI Jury consensus?

RMTI's 12-month base price target is $5.96 (range $4.65 to $13.55), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: RMTI RQD Cockpit RMTI 12M Forecast RMTI Earnings & Move RMTI Dividends & DRIP RMTI Insiders & 13F RMTI Whale Options RMTI Profit Sankey RMTI News & Why

ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RMTI — Rockwell Medical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:48:51Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, RMTI carries an RQD Score of 25, grade E, verdict "Roarable Strong Sell — Forensic Risk / Avoid." Each of the five pillars is scored out of 20:

Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -10.6% and an FCF yield of -2.24%. For a prospective investor, this means the business is currently not generating a return on invested capital or positive free cash flow, so the equity case rests on a future operating turnaround rather than present cash generation.
Whale 13F Flow: 6 / 20. The rating labels this pillar as institutional accumulation and options positioning. The source data does not provide the underlying 13F holdings or options detail, so the score can be read as modest institutional signal strength without further itemization.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow, and it is the lowest-scoring pillar. A low score here indicates insider and related-party activity provides little support for the thesis. The news wire also references a CEO sale of 1,000 shares, which is consistent with this weak reading.
Macro Regime Fit: 6 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. A beta of 1.0 means the stock is expected to move in line with the market, so macro tailwinds would not be amplified for this name.
Forensic Balance Sheet: 5 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.24. The Z-score sits in a range that warrants caution, and the F-score indicates weak fundamental quality signals.

Investor implications. The upside case depends on a reversal from negative operating margin (-6.8%) and negative net margin (-7.7%) toward profitability. The valuation tradeoff is that the market cap of $29.5M sits against a 52-week range of $4.89 to $12.9 and a current price of $7.31, but earnings-based valuation multiples are not available in source data, so value cannot be assessed on earnings. The lowest-scoring pillars (insider conviction and fundamental cash engine) are the primary reasons the composite rating is weak.

Business

Rockwell Medical Inc. (RMTI) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its specific products, customers, or revenue model beyond reported revenue figures in the SEC financials. The profile lists a market capitalization of $0.0B, which differs from the $29.5M in market data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$69.3M	$-4.7M	$-5.3M	N/A	$-0.7M	$10.7M	$8.8M
FY 2024	$101.5M	$0.6M	$-0.5M	N/A	$4.2M	$15.7M	$8.5M
FY 2023	$0.0M	$-6.7M	$-8.4M	N/A	$-9.4M	N/A	N/A

Per the SEC financials, revenue declined from $101.5M in FY 2024 to $69.3M in FY 2025, and operating income moved from $0.6M to $-4.7M. Per the market data, gross margin is 16.9%, operating margin -6.8%, and net margin -7.7%, with ROIC at -10.6%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, and Debt/Equity is 0.24. Cash of $10.7M against debt of $8.8M in FY 2025 describes a balance sheet with limited headroom. Piotroski and Altman values are as reported in the rating and are not independently recalculated.

Recent Catalysts & News Wire Analysis

Earnings release scheduled. Per the news wire, Rockwell Medical will release third quarter 2026 results on Thursday, November 12, 2026 (YELLOW, MARKET WIRE).
Workplace recognition. Per the news wire, the company was ranked No. 16 on the 2026 Fortune "Best Workplaces in Manufacturing & Production" list (YELLOW, MARKET WIRE).
Conference participation. Per the news wire, Rockwell Medical will exhibit at ASN Kidney Week 2026 (YELLOW, MARKET WIRE).
Insider sale. Per the news wire, a CEO sale of 1,000 shares was reported (YELLOW, MARKET WIRE).
Risk watch item. Per the news wire, a headline references a wider-than-expected Q2 2026 loss with EPS missing consensus by 41.84% (RED, RISK WATCH). The headline's source attribution is unusual and the figure should be confirmed against primary filings.
Proprietary signals. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Open Questions

What are the company's specific products, customers, and revenue drivers behind the decline from $101.5M to $69.3M in revenue?
What is the path to positive operating and free cash flow, given FY 2025 FCF of $-0.7M and operating income of $-4.7M?
Which earnings-based valuation metrics (P/E, EV/EBITDA, EPS) apply, since these are not available in source data?
Does the RQD insider-conviction pillar reflect a broader pattern of selling, and what do the underlying Form 4 filings show?
How does the Piotroski F-Score of 3/9 and Altman Z-Score of 2.5 compare against the company's own history, given that FY 2023 cash and debt are not available?

RMTI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rockwell Medical Inc. (RMTI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RMTI Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 18h ago

Rockwell Medical to Release Third Quarter 2026 Results on Thursday, November 12, 2026

Yahoo Finance report covering Rockwell Medical Inc. (RMTI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 21h ago

Rockwell Medical Ranked No. 16 on the 2026 Fortune ‘Best Workplaces in Manufacturing & Production’ List

Yahoo Finance report covering Rockwell Medical Inc. (RMTI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Rockwell Medical earns Fortune ranking. Rockwell Medical stock is valued at USD 31.0 million

ad-hoc-news.de report covering Rockwell Medical Inc. (RMTI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 1d ago

Rockwell Medical to Exhibit at ASN Kidney Week 2026

Business Wire report covering Rockwell Medical Inc. (RMTI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Rockwell Medical CEO sells 1,000 shares: what it means for Rockwell Medical stock

ad-hoc-news.de report covering Rockwell Medical Inc. (RMTI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

RMTI Q2 2026 Earnings: Wider-Than-Expected Loss as EPS Misses Consensus by 41.84% - ROA Comparison

https://www.dars.gov.et/ report covering Rockwell Medical Inc. (RMTI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Rockwell Medical stock: Dialysis portfolio headed to ASN Kidney Week

ad-hoc-news.de report covering Rockwell Medical Inc. (RMTI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RMTI Bull vs. Bear Conversation Board — What's Your Call at $7.07?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RMTI 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $6.43 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RMTI (E • RQD 25/100) a Buy at $7.31?

Welcome to the RMTI (Rockwell Medical Inc.) Roar Pit. Current RQD Composite is 25/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.63 (-23.0%)

Spot @ $7.31

Pump the brakes on RMTI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RMTI, but look at what you are paying: current EV/EBITDA multiples with 16.9% gross margins. Unless Rockwell Medical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $9.21 (+26.0%)

Spot @ $7.31

RMTI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RMTI, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $7.31 (52-wk range $4.89 - $12.90), any beat on forward guidance forces shorts and underweight funds to chase.